NOVABRIDGE BIOSCIENCES (NBP) Stock Fundamental Analysis

NASDAQ:NBP • US44975P1030

3.23 USD
-0.16 (-4.72%)
Last: Feb 12, 2026, 01:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall NBP gets a fundamental rating of 3 out of 10. We evaluated NBP against 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NBP as it has an excellent financial health rating, but there are worries on the profitability. NBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year NBP has reported negative net income.
  • NBP had negative earnings in 4 of the past 5 years.
  • In the past 5 years NBP reported 4 times negative operating cash flow.
NBP Yearly Net Income VS EBIT VS OCF VS FCFNBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

  • The Return On Assets of NBP (-8.85%) is better than 84.51% of its industry peers.
  • Looking at the Return On Equity, with a value of -9.48%, NBP belongs to the top of the industry, outperforming 88.15% of the companies in the same industry.
Industry RankSector Rank
ROA -8.85%
ROE -9.48%
ROIC N/A
ROA(3y)-42.77%
ROA(5y)-32.5%
ROE(3y)-60.95%
ROE(5y)-45.12%
ROIC(3y)N/A
ROIC(5y)N/A
NBP Yearly ROA, ROE, ROICNBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBP Yearly Profit, Operating, Gross MarginsNBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • NBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NBP has more shares outstanding
  • Compared to 5 years ago, NBP has more shares outstanding
  • There is no outstanding debt for NBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NBP Yearly Shares OutstandingNBP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBP Yearly Total Debt VS Total AssetsNBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 6.64 indicates that NBP is not in any danger for bankruptcy at the moment.
  • NBP has a Altman-Z score of 6.64. This is in the better half of the industry: NBP outperforms 76.29% of its industry peers.
  • There is no outstanding debt for NBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.64
ROIC/WACCN/A
WACC12.33%
NBP Yearly LT Debt VS Equity VS FCFNBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • NBP has a Current Ratio of 14.47. This indicates that NBP is financially healthy and has no problem in meeting its short term obligations.
  • NBP has a better Current ratio (14.47) than 90.82% of its industry peers.
  • A Quick Ratio of 14.47 indicates that NBP has no problem at all paying its short term obligations.
  • NBP has a better Quick ratio (14.47) than 90.82% of its industry peers.
Industry RankSector Rank
Current Ratio 14.47
Quick Ratio 14.47
NBP Yearly Current Assets VS Current LiabilitesNBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.96% over the past year.
  • Looking at the last year, NBP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)75.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.12% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.9%
EPS Next 2Y28.05%
EPS Next 3Y16.12%
EPS Next 5Y13.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBP Yearly Revenue VS EstimatesNBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 2033 0 500M 1B 1.5B
NBP Yearly EPS VS EstimatesNBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBP Price Earnings VS Forward Price EarningsNBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBP Per share dataNBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • NBP's earnings are expected to grow with 16.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y16.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NBP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVABRIDGE BIOSCIENCES

NASDAQ:NBP (2/12/2026, 1:04:59 PM)

3.23

-0.16 (-4.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20
Earnings (Next)04-01
Inst Owners27.91%
Inst Owner ChangeN/A
Ins Owners0.56%
Ins Owner ChangeN/A
Market Cap372.31M
Revenue(TTM)N/A
Net Income(TTM)-24.54M
Analysts86
Price Target8.5 (163.16%)
Short Float %15.19%
Short Ratio7.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-1
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.85%
ROE -9.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.77%
ROA(5y)-32.5%
ROE(3y)-60.95%
ROE(5y)-45.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.47
Quick Ratio 14.47
Altman-Z 6.64
F-ScoreN/A
WACC12.33%
ROIC/WACCN/A
Cap/Depr(3y)76.13%
Cap/Depr(5y)97.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.09%
EPS Next Y89.9%
EPS Next 2Y28.05%
EPS Next 3Y16.12%
EPS Next 5Y13.12%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y70.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.07%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABRIDGE BIOSCIENCES / NBP FAQ

Can you provide the ChartMill fundamental rating for NOVABRIDGE BIOSCIENCES?

ChartMill assigns a fundamental rating of 3 / 10 to NBP.


What is the valuation status of NOVABRIDGE BIOSCIENCES (NBP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVABRIDGE BIOSCIENCES (NBP). This can be considered as Overvalued.


How profitable is NOVABRIDGE BIOSCIENCES (NBP) stock?

NOVABRIDGE BIOSCIENCES (NBP) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for NBP stock?

The Earnings per Share (EPS) of NOVABRIDGE BIOSCIENCES (NBP) is expected to grow by 89.9% in the next year.